Two Sigma Investments
TRDA icon

Two Sigma Investments’s Entrada Therapeutics TRDA Stock Holding History

Two Sigma Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
46,402
+1,800
+4% +$17.3K ﹤0.01% 4437
2026
Q1 		$563K Sell
44,602
-4,700
-10% -$53.9K ﹤0.01% 3662
2025
Q4 		$507K Sell
49,302
-43,892
-47% -$370K ﹤0.01% 3296
2025
Q3 		$541K Buy
+93,194
New +$545K ﹤0.01% 2947

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Two Sigma Investments's TRDA Position: Q2 2026 in Review

Two Sigma Investments increased its Entrada Therapeutics (TRDA) stake by 4% in Q2 2026, buying an estimated $17.3K and bringing the position to 46,402 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #4437.

Two Sigma Investments first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $563K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Two Sigma Investments held 46,402 shares of Entrada Therapeutics worth $342K as of Q2 2026.
  • Two Sigma Investments bought 1,800 Entrada Therapeutics shares in Q2 2026, an estimated $17.3K.
  • Entrada Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #4437 holding.
  • Two Sigma Investments first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Two Sigma Investments's Entrada Therapeutics position peaked at $563K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.